Acute lymphoblastic leukemia

This study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…

This Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…

This trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…

This trial tests whether adding lishatoclax to standard chemotherapy, targeted drugs, or immunotherapies can improve remission rates in adults newly diagnosed with acute lymphoblastic leukemia (ALL). Researchers will enroll 30 patients across three subtypes: Philadelphia chromoso…

This trial tests whether a weight-loss medication called phentermine/topiramate, combined with healthy lifestyle counseling, can safely reduce obesity in adolescents and young adults who have survived leukemia or lymphoma. Participants are randomly assigned to receive either the …

This trial is investigating whether a new drug called sonrotoclax, when combined with other anti-cancer medicines, is safe and effective for children and adolescents with acute myeloid leukemia (AML) or B-cell acute lymphoblastic leukemia (ALL) that has returned or not responded …

This study tests whether a drug called blinatumomab, given as a simple injection under the skin, can control small amounts of leftover leukemia cells (called measurable residual disease, or MRD) in adults with B-cell acute lymphoblastic leukemia. The goal is to prevent the cancer…

This early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand si…

This trial tests whether an experimental cell therapy called agenT-797 is safe for people receiving a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Participants get an infusion of agenT-797 about a week after their transplant. The main goal is …

This trial tests whether a social media campaign, co-created with young adult cancer survivors who are also online influencers, can improve how consistently adolescents and young adults (ages 15–25) with acute lymphoblastic leukemia take their daily oral chemotherapy. Participant…

This early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized c…

This early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refracto…

This trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…

This phase 2 trial tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes. About 180 participants aged 15-60 will be randomly…

This phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…

This early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This study tests whether adding SHR2554 and azacitidine to standard chemotherapy before a stem cell transplant can lower the chance of cancer returning in people aged 15-60 with high-risk or relapsed leukemia or myelodysplastic syndromes. Half the participants will get the new dr…

This early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…

This trial tests a new treatment called SHB-02-CD19, which uses a patient's own immune cells engineered to attack cancer cells that have a protein called CD19. It is for children and adults with B-cell cancers (like leukemia or lymphoma) that have come back or not responded to at…

This phase 2 trial tests whether adding asciminib to standard tyrosine kinase inhibitors can prevent relapse in patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia after a stem cell transplant. 45 participan…

This phase 2 trial tests whether combining olverembatinib (a targeted pill) with inotuzumab ozogamicin (an antibody-drug conjugate) can clear remaining leukemia cells in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who still have detectable …

This study tests a new treatment plan for adults up to 65 years old with a type of leukemia called Ph-negative ALL. The goal is to see if adding an immunotherapy drug called blinatumomab improves survival compared to the previous treatment plan. About 330 participants will receiv…

This study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…

This study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…

This study tests an experimental antibody drug called A-319 for people with a type of leukemia (B-ALL) that has come back or not fully cleared after chemotherapy. The drug is given as a shot under the skin and aims to help the immune system attack cancer cells. The main goals are…

This study reviews medical records of 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received ponatinib as their first treatment in regular care. Researchers want to see how many patients achieve a complete molecular response (undetectable leukem…

This study tests whether giving the antibiotic levofloxacin to children with acute lymphoblastic leukemia (ALL) can delay or prevent the first episode of febrile neutropenia (fever with low white blood cells) during early chemotherapy. About 124 children aged 1 to 18 will receive…

This study tests a new drug called BEBT-908 combined with chemotherapy in adults with a rare, high-risk form of acute lymphoblastic leukemia (ALL) who are in remission but still have tiny amounts of cancer cells detectable. The goal is to see if the combo can clear those leftover…

This large international study looks for better ways to manage stem cell transplants in children and young adults with high-risk or relapsed acute lymphoblastic leukemia (ALL). The goal is to reduce serious complications and long-term side effects while keeping the transplant's p…

This early study tests a new drug called STR-P004 in 11 adults with a type of leukemia (ALL) that has come back or not responded to standard treatments. The main goals are to check if the drug is safe, find the right dose, and see if it helps fight the cancer. Participants will r…

This trial tests a combination of three drugs—capivasertib, venetoclax, and dexamethasone—in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The study has two phases: first, to find the safest dose, and sec…

This early-stage trial tests a personalized cell therapy called CD19/22 CAR-T cells in 17 adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lymphoma. Patients receive their own immune cells that have been reprogrammed to target and kill cancer cells. The s…

Researchers are testing whether removing a specific type of immune cell, called CD45RA-positive naive T cells, from donor stem cells can prevent graft-versus-host disease in older adults undergoing stem cell transplants for acute leukemia or myelodysplastic syndrome. The trial en…

Researchers are studying whether aloe vera mouthwash can prevent or reduce the severity of oral mucositis, a painful mouth sore that often affects people receiving chemotherapy for acute leukemia. The trial compares aloe vera mouthwash plus usual care against usual care alone in …

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This trial tests whether a 10-week mobile health program, called ReSeT2, can reduce the time adolescents and young adults with acute lymphoblastic leukemia (ALL) spend sitting during maintenance therapy. Participants aged 13-22 will be randomly assigned to either the intervention…

This study tests if a gentle, non-invasive electrical stimulation on specific acupoints can reduce nerve pain caused by chemotherapy in children aged 10-17 with acute lymphoblastic leukemia. The treatment is given for 8 weeks, and researchers will check if it helps with pain, mov…

This study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…

This study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …

This study looks at whether a blood test that detects tumor DNA (ctDNA) can give the same information as bone marrow tests in children with acute leukemia. Researchers will compare ctDNA results with standard bone marrow checks for minimal residual disease. The goal is to see if …

This pilot study tests whether adults aged 65 and older with acute leukemia can use a digital platform to complete health questionnaires from home. Twenty participants will fill out surveys about their quality of life and symptoms on a tablet or phone, with results sent directly …

This study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…

This study is testing a 6-session family program called NOURISH-ALL for children ages 2-12 with acute lymphoblastic leukemia (ALL) and their caregivers. The program focuses on healthy eating, physical activity, and reducing family stress during early treatment phases. The main go…

This study will collect blood and bone marrow samples from 55 adults with acute leukemia or myelodysplastic syndrome. Researchers want to understand how natural killer (NK) cells interact with cancer cells over time. The goal is to identify genetic markers and immune patterns tha…

This observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to unders…

This study looks at why some people with acute lymphoblastic leukemia (ALL) have severe allergic reactions to the drug asparaginase. Researchers will collect blood cells from 20 patients and test them in the lab to see if certain immune cells (T cells) become overactive. The goal…

This study aims to understand why some children and young adults with acute lymphoblastic leukemia (ALL) develop severe allergic reactions to PEG-asparaginase, a crucial chemotherapy drug. Researchers will collect blood and bone marrow samples from 45 patients (20 with allergies …

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …

This study looks at how long the drug calaspargase pegol stays at effective levels in the blood of children and young adults with acute lymphoblastic leukemia or lymphoma. Researchers will measure drug activity and check for links to side effects. The goal is to better understand…

This study will create a structured follow-up program for 400 children and young adults who have survived blood cancers like leukemia and lymphoma. Researchers want to better track and understand long-term health problems that can appear years after treatment. The goal is to impr…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…